Empasiprubart for CIDP

(emnergize Trial)

This trial aims to test the effectiveness and safety of empasiprubart for adults with CIDP, a condition causing weakness and numbness in the arms and legs. In the first part, participants will receive either the new treatment (empasiprubart IV, an intravenous infusion) or a placebo for six months. Afterward, all participants will receive the actual treatment for two years. This trial suits individuals diagnosed with CIDP who experience ongoing symptoms and are willing to stop current CIDP treatments to try something new. As a Phase 3 trial, it represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

Yes, if you are currently receiving treatment for CIDP, you will need to stop your current CIDP medications before starting the study medication.

Research has shown that empasiprubart has been tested in people with various health conditions. In one study, researchers compared it to another treatment for CIDP, a nerve disorder that causes weakness and numbness, to determine if empasiprubart could be an effective treatment option.

In another study involving patients with a different condition, empasiprubart was generally well-tolerated, with most participants not experiencing serious side effects. Some experienced mild to moderate side effects, but these were not severe enough to discontinue treatment.

Researchers are excited about empasiprubart for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) because it offers a novel approach compared to current treatments like corticosteroids, immunoglobulins, and plasma exchange. Most existing treatments aim to suppress the immune system broadly or remove harmful antibodies, but empasiprubart targets specific immune pathways more precisely, potentially reducing side effects and improving outcomes. Additionally, empasiprubart is administered intravenously, which may ensure more consistent delivery and absorption in the body. This targeted and precise mechanism could lead to improved management of CIDP symptoms with fewer complications.

Research has shown that empasiprubart blocks certain proteins, C3 and C5, which cause inflammation and tissue damage. This action may help reduce inflammation and damage in individuals with CIDP, a condition that leads to nerve damage. Although empasiprubart is not yet approved for treating CIDP, this trial will compare it to a placebo to evaluate its effectiveness in managing CIDP symptoms. Further research is needed to confirm its efficacy.¹²³⁶⁷